SI3193917T1 - Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce - Google Patents

Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce

Info

Publication number
SI3193917T1
SI3193917T1 SI201531744T SI201531744T SI3193917T1 SI 3193917 T1 SI3193917 T1 SI 3193917T1 SI 201531744 T SI201531744 T SI 201531744T SI 201531744 T SI201531744 T SI 201531744T SI 3193917 T1 SI3193917 T1 SI 3193917T1
Authority
SI
Slovenia
Prior art keywords
dioxygenase
particles
compositions containing
vaccine compositions
containing tryptophan
Prior art date
Application number
SI201531744T
Other languages
English (en)
Slovenian (sl)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of SI3193917T1 publication Critical patent/SI3193917T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
SI201531744T 2014-09-17 2015-09-15 Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce SI3193917T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470571 2014-09-17
PCT/DK2015/050274 WO2016041560A1 (en) 2014-09-17 2015-09-15 Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
EP15774851.8A EP3193917B9 (en) 2014-09-17 2015-09-15 Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

Publications (1)

Publication Number Publication Date
SI3193917T1 true SI3193917T1 (sl) 2022-02-28

Family

ID=51661826

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531744T SI3193917T1 (sl) 2014-09-17 2015-09-15 Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce

Country Status (18)

Country Link
US (2) US10736950B2 (cg-RX-API-DMAC7.html)
EP (2) EP3193917B9 (cg-RX-API-DMAC7.html)
JP (1) JP6811710B2 (cg-RX-API-DMAC7.html)
CN (1) CN106999557B (cg-RX-API-DMAC7.html)
AU (1) AU2015317446B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959197C (cg-RX-API-DMAC7.html)
CY (1) CY1124738T1 (cg-RX-API-DMAC7.html)
DK (1) DK3193917T3 (cg-RX-API-DMAC7.html)
ES (1) ES2891902T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211540T2 (cg-RX-API-DMAC7.html)
HU (1) HUE056414T2 (cg-RX-API-DMAC7.html)
IL (1) IL251101B (cg-RX-API-DMAC7.html)
LT (1) LT3193917T (cg-RX-API-DMAC7.html)
PL (1) PL3193917T3 (cg-RX-API-DMAC7.html)
PT (1) PT3193917T (cg-RX-API-DMAC7.html)
SI (1) SI3193917T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016041560A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701179B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110628736B (zh) * 2019-10-09 2021-05-11 扬州大学 色氨酸2,3双加氧酶突变体及其制备方法和应用
CN111012919B (zh) * 2019-12-23 2021-06-01 山东大学 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
JP2024522256A (ja) * 2021-05-17 2024-06-12 ウィスコンシン アラムニ リサーチ ファンデーション 免疫寛容を誘導するための合成タンパク質
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP1522594A3 (en) * 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
DE102004039196B4 (de) * 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
PL3320912T3 (pl) * 2008-04-17 2021-10-25 Io Biotech Aps Immunoterapia na bazie 2,3-dioksygenazy indoloaminy
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
SI2768524T1 (sl) 2011-10-17 2022-09-30 Io Biotech Aps Imunoterapija na osnovi PD-L1
GB201120860D0 (en) * 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy

Also Published As

Publication number Publication date
WO2016041560A1 (en) 2016-03-24
JP6811710B2 (ja) 2021-01-20
CY1124738T1 (el) 2022-07-22
ES2891902T3 (es) 2022-01-31
HRP20211540T2 (hr) 2022-05-13
PL3193917T3 (pl) 2022-01-17
ES2891902T9 (es) 2022-03-02
EP3193917B1 (en) 2021-08-18
NZ730708A (en) 2024-01-26
AU2015317446A1 (en) 2017-04-20
US20210023191A1 (en) 2021-01-28
DK3193917T3 (da) 2021-10-04
HUE056414T2 (hu) 2022-02-28
EP3193917A1 (en) 2017-07-26
PT3193917T (pt) 2021-10-20
IL251101A0 (en) 2017-04-30
LT3193917T (lt) 2021-11-25
ZA201701179B (en) 2021-05-26
CA2959197A1 (en) 2016-03-24
US11878053B2 (en) 2024-01-23
EP3919074A1 (en) 2021-12-08
CN106999557B (zh) 2021-04-20
EP3193917B9 (en) 2022-02-16
CN106999557A (zh) 2017-08-01
IL251101B (en) 2021-05-31
JP2017533182A (ja) 2017-11-09
US10736950B2 (en) 2020-08-11
HRP20211540T1 (hr) 2021-12-24
AU2015317446B2 (en) 2020-08-13
CA2959197C (en) 2023-03-14
US20170239337A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
IL251532A0 (en) Modified virus-like particles of cmv
DK3188717T3 (da) Formulering, der omfatter partikler
BR112016023628A2 (pt) composições farmacêuticas.
DK3151672T3 (da) Forbedrede t-celle-sammensætninger
LT3206497T (lt) Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
HRP20181479T1 (hr) Tekući farmaceutski sastav
DK3215173T3 (da) Glycopeptidsammensætninger
DK3179967T3 (da) Mundkøler
IL249823A0 (en) Meningococcus vaccines
DK3129007T3 (da) Vaccinesammensætninger
EP3560512A4 (en) COMPOSITION OF VACCINE AGAINST ZONA
EA202092926A3 (ru) Лиофилизированные составы, содержащие фактор ix
SI3193917T1 (sl) Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
HUE051900T2 (hu) Íz-leplezett orális gyógyászati készítmény
DK3200827T3 (da) Sammensætninger
DK3089740T3 (da) Farmaceutisk sammensætning
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid
BR112017004882A2 (pt) composição farmacêutica oral.
TH1501005760A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1501005765A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1501004634A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
CO6990731A2 (es) Composiciones de cuidado oral
CO6990733A2 (es) Composiciones de cuidado oral